Pfizer made one thing clear this week: It's officially back in the obesity race.

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

Feb 3 (Reuters) - Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up ...

The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.

Pfizer (PFE) chairman and CEO Albert Bourla joins Julie Hyman on Market Domination to talk more about the pharmaceutical ...

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can.

Is Pfizer stock a buy at under 9x earnings? Yes. It is.

In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a ...

Pfizer's stock has risen off its lows, but remains 50% below its 2021 highs.